<DOC>
	<DOC>NCT00926224</DOC>
	<brief_summary>The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients &gt; 28 kg/m² with various liver diseases in patients with chronic liver disease scheduled for a liver biopsy.</brief_summary>
	<brief_title>Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Patient of at least 18 years of age Patient able to give written informed consent form Patient with a BMI superior or equal to 28kg/m² Patient scheduled to have a liver biopsy within 1 month after the enrollment or with a liver biopsy performed within 6 months before the enrollment. Patient for which abdominal ultrasound is technically possible Unable or unwilling to provide written informed consent Confirmed diagnosis and/or history of malignancy, or other terminal disease Patients with clinical ascites Pregnant women Patient with a BMI &lt; 28 kg/m² Patients with any active implantable medical device (such as pacemaker or defibrillator) Transplanted patient and patient with heart disease Refusal to undergo a liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Adult patients with chronic liver disease scheduled for a liver biopsy and a BMI superior or equal to 28 kg/m²</keyword>
</DOC>